Oral Inosine Persistently Elevates Plasma antioxidant capacity in Parkinson's disease

Movement Disorders

Volumn 31, Issue 3, 2016, Pages 417-421

  Bhattacharyya, Shamik ^a,c,d   Bakshi, Rachit ^a,d   Logan, Robert ^a   Ascherio, Alberto ^b,d   Macklin, Eric A ^a,d   Schwarzschild, Michael A ^a,d  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Antioxidant; Inosine; Parkinson's disease; Uric acid urate

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; DNA; INOSINE; MONOAMINE OXIDASE B INHIBITOR; PLACEBO; URATE; ANTIOXIDANT; URIC ACID;

ADULT; ANTIOXIDANT ACTIVITY; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CONTROLLED STUDY; DNA ADDUCT; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FERRIC REDUCING ANTIOXIDANT POWER; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OXIDATION; PARKINSON DISEASE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; URIC ACID BLOOD LEVEL; URINALYSIS; BLOOD; DISEASE COURSE; DRUG EFFECTS; OXIDATIVE STRESS; PHYSIOLOGY; TREATMENT OUTCOME;

ANTIOXIDANTS; DISEASE PROGRESSION; FEMALE; HUMANS; INOSINE; MALE; MIDDLE AGED; OXIDATIVE STRESS; PARKINSON DISEASE; TREATMENT OUTCOME; URIC ACID;

EID: 84961971180     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.26483     Document Type: Article

References (28)

1. De Lau LM, Koudstaal PJ, Hofman A, Breteler MM. Serum uric acid levels and the risk of Parkinson disease. Ann Neurol 2005;58:797-800.
2. Ascherio A, LeWitt PA, Xu K, Eberly S, Watts A, Matson WR, et al. Urate as a predictor of the rate of clinical decline in Parkinson disease. Arch Neurol 2009;66:1460-1468.
3. Schwarzschild MA, Schwid SR, Marek K, Watts A, Lang AE, Oakes D, et al. Serum urate as a predictor of clinical and radiographic progression in Parkinson disease. Arch Neurol 2008;65:716-723.
4. Davis JW, Grandinetti A, Waslien CI, Ross GW, White LR, Morens DM. Observations on serum uric acid levels and the risk of idiopathic Parkinson's disease. Am J Epidemiol 1996;144:480-484.
5. Weisskopf MG, O'Reilly E, Chen H, Schwarzschild MA, Ascherio A. Plasma urate and risk of Parkinson's disease. Am J Epidemiol 2007;166:561-567.
6. Moccia M, Picillo M, Erro R, Vitale C, Longo K, Amboni M, et al. Presence and progression of non-motor symptoms in relation to uric acid in de novo Parkinson's disease. Eur J Neurol Off J Eur Fed Neurol Soc 2015;22:93-98.
7. Chen X, Burdett TC, Desjardins CA, Logan R, Cipriani S, Xu Y, et al. Disrupted and transgenic urate oxidase alter urate and dopaminergic neurodegeneration. Proc Natl Acad Sci U S A 2013;110:300-305.
8. Gong L, Zhang QL, Zhang N, Hua WY, Huang YX, Di PW, et al. Neuroprotection by urate on 6-OHDA-lesioned rat model of Parkinson's disease: linking to Akt/GSK3β signaling pathway. J Neurochem 2012;123:876-885.
9. Jenner P. Oxidative stress in Parkinson's disease. Ann Neurol 2003;53(Suppl 3):S26-S38; discussion, S36-S38.
10. Smeyne M, Smeyne RJ. Glutathione metabolism and Parkinson's disease. Free Radic Biol Med 2013;62:13-25.
11. Subramaniam SR, Chesselet MF. Mitochondrial dysfunction and oxidative stress in Parkinson's disease. Prog Neurobiol 2013;106-107:17-32.
12. Chen X, Wu G, Schwarzschild MA. Urate in Parkinson's disease: more than a biomarker? Curr Neurol Neurosci Rep 2012;12:367-375.
13. Cipriani S, Bakshi R, Schwarzschild MA. Protection by inosine in a cellular model of Parkinson's disease. Neuroscience 2014;274:242-249.
14. The Parkinson Study Group SURE-PD Investigators, Schwarzschild MA, Ascherio A, Beal MF, Cudkowicz ME, Curhan GC, et al. Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial. JAMA Neurol 2014;71:141-150.
15. Wu LL, Chiou CC, Chang PY, Wu JT. Urinary 8-OHdG: a marker of oxidative stress to DNA and a risk factor for cancer, atherosclerosis and diabetics. Clin Chim Acta Int J Clin Chem 2004;339:1-9.
16. Benzie IF, Strain JJ. Ferric reducing/antioxidant power assay: direct measure of total antioxidant activity of biological fluids and modified version for simultaneous measurement of total antioxidant power and ascorbic acid concentration. Methods Enzymol 1999;299:15-27.
17. Benzie IF, Strain JJ. The ferric reducing ability of plasma (FRAP) as a measure of "antioxidant power": the FRAP assay. Anal Biochem 1996;239:70-76.
18. Berry EM, Kohen R. Is the biological antioxidant system integrated and regulated? Med Hypotheses 1999;53:397-401.
19. Choy C, Benzie I, Cho P. Antioxidants in tears and plasma: inter-relationships and effect of vitamin C supplementation. Curr Eye Res 2003;27:55-60.
20. Karajibani M, Hashemi M, Montazerifar F, Bolouri A, Dikshit M. The status of glutathione peroxidase, superoxide dismutase, vitamins A, C, E and malondialdehyde in patients with cardiovascular disease in Zahedan, Southeast Iran. J Nutr Sci Vitaminol (Tokyo) 2009;55:309-316.
21. Gupta S, Gambhir JK, Kalra O, Gautam A, Shukla K, Mehndiratta M, et al. Association of biomarkers of inflammation and oxidative stress with the risk of chronic kidney disease in type 2 diabetes mellitus in North Indian population. J Diabetes Complications 2013;27:548-52.
22. Sekler A, Jiménez JM, Rojo L, Pastene E, Fuentes P, Slachevsky A, et al. Cognitive impairment and Alzheimer's disease: links with oxidative stress and cholesterol metabolism. Neuropsychiatr Dis Treat 2008;4:715-22.
23. Zamora-Ros R, Serafini M, Estruch R, Lamuela-Raventós RM, Martínez-González MA, Salas-Salvadó J, et al. Mediterranean diet and non enzymatic antioxidant capacity in the PREDIMED study: evidence for a mechanism of antioxidant tuning. Nutr Metab Cardiovasc Dis NMCD 2013;23:1167-1174.
24. Estruch R, Ros E, Salas-Salvadó J, Covas MI, Corella D, Arós F, et al. Primary prevention of cardiovascular disease with a Mediterranean diet. N Engl J Med 2013;368:1279-1290.
25. Lönnrot K, Metsä-Ketelä T, Molnár G, Ahonen JP, Latvala M, Peltola J, et al. The effect of ascorbate and ubiquinone supplementation on plasma and CSF total antioxidant capacity. Free Radic Biol Med 1996;21:211-217.
26. Uotila JT, Kirkkola AL, Rorarius M, Tuimala RJ, Metsä-Ketelä T. The total peroxyl radical-trapping ability of plasma and cerebrospinal fluid in normal and preeclamptic parturients. Free Radic Biol Med 1994;16:581-590.
27. Sato S, Mizuno Y, Hattori N. Urinary 8-hydroxydeoxyguanosine levels as a biomarker for progression of Parkinson disease. Neurology 2005;64:1081-1083.
28. AlDakheel A, Kalia LV, Lang AE. Pathogenesis-targeted, disease-modifying therapies in Parkinson disease. Neurother J Am Soc Exp Neurother 2014;11:6-23.